NEWS RELEASE

First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study

3/16/2021

Veeva eConsent makes it easier for patients to understand and provide electronic informed consent

Milestone accelerates industry's move toward paperless, patient-centric trials

BARCELONA, Spain--(BUSINESS WIRE)-- **Veeva Systems** (NYSE: VEEV) today announced that Veeva eConsent, a **MyVeeva for Patients** application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center. Veeva eConsent is the first validated application for sites and patients that transforms the consent process from manual and paper-based to an end-to-end digital experience. Patients can review documents and protocols and provide consent via mobile phone, streamlining the experience for both patients and sites.

"As one of the first sites using Veeva eConsent, we're excited to collaborate with Veeva to help the industry shift from paper to digital consent for the benefit of patients and clinical research," said Charles Sydnor, CCRA, ACRP-CP, project manager at Crofoot Research Center. "Veeva eConsent makes the process easy for our patients and allows us to break down the barriers of paper and location, expanding the reach of our study."

COVID-19 accelerated the industry's move to digital solutions that enable decentralized trials and keep studies on track, speed study start-up, and improve trial execution. Veeva eConsent enables this transformation through digital consent document creation, approval, and exchange. Sites can use the application for trials across sponsors and automate the flow of consent documents to the investigator site file (ISF) for better collaboration and greater speed.

With Veeva eConsent, sponsors get real-time visibility into patient consent status, date, and version and monitors

and site personnel gain remote access to trial information. Reducing the time spent on administrative tasks increases site and patient engagement throughout a study.

“In just six months, we went from concept to the first patient using Veeva eConsent,” said Tim Davis, vice president, MyVeeva for Patients at Veeva Systems. “This marks a major step forward for the future of paperless, patient-centric trials and we remain focused on continuing to deliver innovations that will help the industry realize this important vision.”

Attend the upcoming webinar on April 29 to hear Crofoot discuss how Veeva eConsent helps sites run more efficient clinical trials and to learn more about Veeva Clinical Network, the industry’s only solution that connects sponsors, sites, and patients to accelerate clinical research.

Additional Information

Connect with Veeva on LinkedIn: **linkedin.com/company/veeva-systems**

Follow @veeva_eu on Twitter: **twitter.com/veeva_eu**

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit **veeva.com/eu**.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and

uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2020. This is available on the company's website at **veeva.com** under the Investors section and on the SEC's website at **sec.gov**. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

View source version on **businesswire.com**: **https://www.businesswire.com/news/home/20210316005107/en/**

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

Source: Veeva Systems